
Browsing restrictions can be lifted for a fee.
-4.89%
Bioage labs, inc.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Bioage labs, inc. (BIOA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BIOA's short-term business performance and financial health. For the latest updates on BIOA's earnings releases, visit this page regularly.
According to the latest financial report, Bioage labs, inc. (BIOA) reported an Operating Profit of -23.14M with an Operating Margin of -1,126.58% this period, representing a growth of 6.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Bioage labs, inc. (BIOA) announced revenue of 2.05M, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Bioage labs, inc. (BIOA) had total debt of 7.13M, with a debt ratio of 0.02. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Bioage labs, inc. (BIOA) held Total Cash and Cash Equivalents of 215.57M, accounting for 0.71 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Bioage labs, inc. (BIOA) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,126.58%%, and net margin of -982%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BIOA's profit trajectory and future growth potential.
According to the past four quarterly reports, Bioage labs, inc. (BIOA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.56. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Bioage labs, inc. (BIOA)'s Free Cash Flow (FCF) for the period is -16.07M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 5.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Bioage labs, inc. (BIOA) has a Price-To-Earnings (PE) ratio of -3.53 and a Price/Earnings-To-Growth (PEG) ratio of 0.39. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.